Biosimilar FSH preparations- are they identical twins or just siblings?

Reproductive Biology and Endocrinology

Volumn 14, Issue 1, 2016, Pages

  Orvieto, Raoul ^a,b   Seifer, David B ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; RECOMBINANT FOLLITROPIN; BIOSIMILAR AGENT; FOLLITROPIN; RECOMBINANT PROTEIN;

BIOCOMPATIBILITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SYNTHESIS; EDITORIAL; FEMALE INFERTILITY; HUMAN; NONHUMAN; OVARY HYPERSTIMULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; FEMALE; PREGNANCY; PREGNANCY RATE; TREATMENT OUTCOME;

BIOSIMILAR PHARMACEUTICALS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84974782359     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/s12958-016-0167-8     Document Type: Editorial

References (25)

1. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf ; 2012 Accessed 21 May 2014
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411-9.
3. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changesin quality attributes of glycosylated biopharmaceuticals. NatBiotechnol. 2011;29:310-2.
4. US Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity to a reference protein product, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf; 2012 Accessed 21 May 2014.
5. Padmanabhan V, Lang LL, Sonstein J, Kelch RP, Beitins IZ. Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. J Clin Endocrinol Metab. 1988;67:465-73.
6. Ulloa-Aguirre A, Midgley Jr AR, Beitins IZ, Padmanabhan V. Follicle-stimulating isohormones: characterization and physiological relevance. Endocrine Review. 1995;16:765-87.
7. Zambrano E, Olivares A, Mendez JP, Guerrero L, Díaz-Cueto L, Veldhuis JD, Ulloa-Aguirre A. Dynamics of basal and GnRH-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. J Clin Endocrinol Metab. 1995;80:1647-165.
8. Steelman SL, Pohley FM. Assay of FSH based on the augmentation with hCG. Endocrinology. 1953;53:604-16.
9. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. Structure-function relationship of recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod. 1996;2:361-9.
10. Scientific Discussion- Puregon, EMEA, 2005. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000086/WC500045613.pdf.
11. Olsson H, Sandström R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharm. 2014;54:1299-307.
12. Tal R, Seifer DB. Personalized prediction of live birth: are we there yet? Fertil Steril. 2015;104:283-5.
13. Mulders JW, Derksen M, Swolfs A, Maris F. Prediction of the in vivo biological activity of human recombinant follicle stimulating hormone using quantitative isoelectric focusing. Biologicals. 1997;25:269-81.
14. D'Antonio M, Borrelli F, Datola A, Bucci R, Mascia M, Polletta P, Piscitelli D, Papoian R. Biological characterization of recombinant human follicle stimulating hormone isoforms. Hum Reprod. 1999;14:1160-7.
15. Chappel S. The choice of gonadotrophin isoforms in present and future preparations. What can we expect? In: Kahn JA, editor. Gonadotrophin Isoforms- Facts and Future, Serono Fertility Series. 1997.
16. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotropin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2, CD005354.
17. Orvieto R, Nahum R, Rabinson J, Ashkenazi J, Anteby EY, Meltcer S. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference? Fertil Steril. 2009;91(4 Suppl):1522-5.
18. Yding Andersen C, Westergaard LG, van Wely M. FSH isoform composition of commercial gonadotropin preparations: a neglected aspect? Reprod Biomed Online. 2004;9(2):231-6.
19. Gurgan T, Montjean D, Demirol A, Menezo YJ. Sequential (hFSH (Thorn) recFSH) vs homogenous (hFSH or recFSH alone) stimulation: clinical and biochemical (cumulus cell gene expression) aspects. J Assist Reprod Genet. 2014;31(6):657-65.
20. Gerli S, Di Renzo GC. Establishing a combined stimulation protocol hFSH followed by rFSH might represent a breakthrough in the IVF practice. Eur Rev Med Pharmacol Sci. 2013;17(15):2091-6.
21. Grass J, Pabst M, Chang M, Wozny M, Altmann F. Analysis of recombinant human follicle-stimulating hormone (FSH) by mass spectrometric approaches. Anal Bioanal Chem. 2011;400(8):2427-38.
22. Gervais A, Hammel YA, Pelloux S, Lepage P, Baer G, Carte N, Sorokine O, Strub JM, Koerner R, Leize E, Van Dorsselaer A. Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency. Glycobiology. 2003;13(3):179-89.
23. Rettenbacher M, Andersen AN, Garcia-Velasco JA, Sator M, Barri P, Lindenberg S, van der Ven K, Khalaf Y, Bentin-Ley U, Obruca A, Tews G, Schenk M, Strowitzki T, Narvekar N, Sator K, Imthurn B. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. Reprod Biomed Online. 2015;30(5):504-13.
24. Strowitzki T, Kuczynski W, Mueller A, Bias P. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol. 2016;14:1.
25. Australian Public Assessment Report for Follitropin alfa (rch), march 2016. https://www.tga.gov.au/sites/default/files/auspar-follitropin-alfa-rch-160408.docx